Immunovant (NASDAQ:IMVT) Announces Earnings Results, Beats Estimates By $0.10 EPS

Immunovant (NASDAQ:IMVT) issued its earnings results on Friday. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.10, FiscalAI reports. During the same quarter in the prior year, the firm posted ($0.76) EPS.

Here are the key takeaways from Immunovant’s conference call:

• Phase 2 cutaneous sarcoidosis: BREPA 45 mg produced a ~21.6‑point placebo‑adjusted CSAMI improvement with a 100% ≥10‑point responder rate, rapid separation vs placebo, supportive PROs and no SAEs reported in the study.
• Development and catalyst cadence is heavy in 2026 — a phase 3 program for cutaneous sarcoidosis will start this year, an NDA is filed for dermatomyositis, NIU phase 3 readout is expected in H2 2026, and multiple other trials (mosliciguat, DTT‑RA, 1402 CLE) are fully enrolled or nearing data.
• Financially fortified: Roivant reported a consolidated cash balance of about $4.5 billion and non‑GAAP net loss of $167M for the quarter, which management says provides runway to multiple near‑term development and potential launches.
• Commercial opportunity: Management views BREPA as a multi‑indication orphan franchise (DM, NIU, CS) with high unmet need and expects orphan pricing levers if phase 3 results mirror the strong phase 2 outcomes.
• JV/accounting note: Priovant is 25% owned by Pfizer and Roivant will fully consolidate Priovant’s results while recording Pfizer’s share as a below‑the‑line minority interest; Pfizer’s early dilution protections are exhausted, so future capital raises could require Pfizer to match or lead to dilution.

Immunovant Stock Performance

Immunovant stock traded up $2.19 during mid-day trading on Friday, hitting $26.25. 1,559,955 shares of the company traded hands, compared to its average volume of 1,520,696. Immunovant has a one year low of $12.72 and a one year high of $27.80. The stock has a market cap of $4.60 billion, a price-to-earnings ratio of -9.22 and a beta of 0.54. The stock has a fifty day moving average price of $25.56 and a 200-day moving average price of $20.69.

Analyst Upgrades and Downgrades

IMVT has been the topic of a number of analyst reports. The Goldman Sachs Group boosted their price objective on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Truist Financial lifted their target price on Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Friday, January 9th. Finally, Guggenheim reiterated a “buy” rating and issued a $41.00 target price on shares of Immunovant in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Immunovant currently has a consensus rating of “Moderate Buy” and an average price target of $30.78.

Insider Activity

In other Immunovant news, COO Melanie Gloria sold 12,626 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $23.62, for a total transaction of $298,226.12. Following the sale, the chief operating officer owned 173,511 shares in the company, valued at $4,098,329.82. This trade represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Douglas J. Hughes sold 15,000 shares of Immunovant stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $23.24, for a total value of $348,600.00. Following the sale, the director directly owned 120,773 shares of the company’s stock, valued at approximately $2,806,764.52. This trade represents a 11.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 63,868 shares of company stock worth $1,538,470. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Immunovant

Several hedge funds and other institutional investors have recently bought and sold shares of IMVT. Deep Track Capital LP raised its stake in shares of Immunovant by 2.4% during the third quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after acquiring an additional 228,845 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Immunovant by 12.2% during the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $94,076,000 after purchasing an additional 636,000 shares during the last quarter. Two Seas Capital LP grew its holdings in shares of Immunovant by 22.6% during the 3rd quarter. Two Seas Capital LP now owns 2,762,040 shares of the company’s stock valued at $44,524,000 after purchasing an additional 509,268 shares during the last quarter. ADAR1 Capital Management LLC raised its position in Immunovant by 319.0% in the 3rd quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock worth $36,137,000 after purchasing an additional 1,706,687 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after purchasing an additional 329,354 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.